Learn from the SARS-CoV-2 nucleic acid test to increase the experience of dealing with the “disease X
RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, p...
Saved in:
Published in | BMC infectious diseases Vol. 25; no. 1; pp. 593 - 9 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
24.04.2025
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X".
Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions.
When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative.
In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X". |
---|---|
AbstractList | RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X".
Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions.
When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative.
In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X". BackgroundRT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future “Disease X”.MethodsData from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions.ResultsWhen the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 − 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative.ConclusionsIn summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next “Disease X”. RT-PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X". Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions. When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event ([less than or equal to] 1.72%). However, when the 30 [less than or equal to] Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative. In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X". Background RT-PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X". Methods Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions. Results When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event ([less than or equal to] 1.72%). However, when the 30 [less than or equal to] Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative. Conclusions In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X". Keywords: Retest, False positive, RT-PCR, COVID-19, SARS-CoV-2, Cycle threshold, Disease X Abstract Background RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future “Disease X”. Methods Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions. Results When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 − 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative. Conclusions In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next “Disease X”. RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X".BACKGROUNDRT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X".Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions.METHODSData from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions.When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative.RESULTSWhen the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative.In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X".CONCLUSIONSIn summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X". |
ArticleNumber | 593 |
Audience | Academic |
Author | Yang, Xin Li, Jinming |
Author_xml | – sequence: 1 givenname: Xin surname: Yang fullname: Yang, Xin – sequence: 2 givenname: Jinming surname: Li fullname: Li, Jinming |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40275167$$D View this record in MEDLINE/PubMed |
BookMark | eNqNks1uEzEQx1eoiH7AC3BAlrjAYYs_1uvdE4oiCpEiVWqg4mZ5veONo40d7F1obzwIT8eT4CSlNIgDmoOtmZ__oxn_T7Mj5x1k2XOCzwmpyjeR0ErUOaY8J7iuSS4eZSekECSnjBVHD-7H2WmMK4yJqGj9JDsuMBWclOIk6-aggkMm-DUaloAWk6tFPvXXOUVu1D1YjZS2LRogDmjwyDodQEXYwXCzgWDBaUDeoBZUb12HvtlhuSv__P6jtXFHf36aPTaqj_Ds7jzLPl28-zj9kM8v38-mk3muecWHvCxwrVXZ1mVjDAZNOJCmaRWBirdtsS0wzKs0EnBdGqFqUhNGNRAQvBHAzrLZXrf1aiU3wa5VuJVeWblL-NBJFQabJpO1FsI0GJeUqaRcVg3TGJqKGQ7b7knr7V5rMzZraDW4Iaj-QPSw4uxSdv6rJBSnEDQpvLpTCP7LmFYo1zZq6HvlwI9RMlIXJafpVxL68i905cfg0q4ko5hwSktc_6E6lSawzvjUWG9F5aRighAhaJGo839QKVpYW51MZGzKHzx4ffAgMQPcDJ0aY5SzxdX_s5fXh-yLhxu8X91v_yWA7gEdfIwBzD1CsNyaXO5NLpPJ5c7kUrBfVYnrSw |
Cites_doi | 10.3201/eid2608.201843 10.1101/2020.04.26.20080911 10.3390/diseases11010020 10.1016/j.jhazmat.2024.134201 10.1080/14787210.2022.2089653 10.1016/S1473-3099(21)00146-8 10.1097/JOM.0000000000002138 10.3390/v12060582 10.1016/S2213-2600(20)30453-7 10.1002/anie.202400413 10.1016/j.jmii.2020.02.012 10.1016/j.cmi.2020.10.003 10.1093/ofid/ofab453 10.1093/clinchem/hvaa214 10.1080/17476348.2021.1917389 10.1183/13993003.00360-2021 10.2807/1560-7917.ES.2020.25.50.2000568 10.1128/cmr.00072-23 10.1080/14737159.2020.1757437 10.1080/17476348.2022.2049760 10.3389/fpubh.2023.1240308 10.1016/j.jmoldx.2020.10.008 |
ContentType | Journal Article |
Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QL 7T2 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12879-025-10991-7 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Opposing Viewpoints (Gale in Context) Gale In Context: Science ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2334 |
EndPage | 9 |
ExternalDocumentID | oai_doaj_org_article_9c77fb00623a46d68b3c0eb83f5ebff0 PMC12020272 A837117724 40275167 10_1186_s12879_025_10991_7 |
Genre | Journal Article |
GeographicLocations | China Israel Shanghai China |
GeographicLocations_xml | – name: China – name: Israel – name: Shanghai China |
GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7QL 7T2 7U9 7XB 8FK AZQEC C1K COVID DWQXO H94 K9. M48 M7N PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c585t-6409ca6d96bff0ec15e1bbda1e85dd46d963058334e5c6f7a919132ce1e75b7e3 |
IEDL.DBID | 7X7 |
ISSN | 1471-2334 |
IngestDate | Wed Aug 27 01:24:17 EDT 2025 Thu Aug 21 18:26:54 EDT 2025 Fri Jul 11 18:30:14 EDT 2025 Fri Jul 25 09:19:51 EDT 2025 Tue Jun 17 21:59:21 EDT 2025 Tue Jun 10 20:58:12 EDT 2025 Fri Jun 27 05:13:20 EDT 2025 Fri Jun 27 05:11:48 EDT 2025 Mon Jul 21 05:45:19 EDT 2025 Tue Jul 01 05:03:23 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | COVID‒19 False positive Retest Cycle threshold RT‒PCR Disease X SARS‒CoV‒2 |
Language | English |
License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c585t-6409ca6d96bff0ec15e1bbda1e85dd46d963058334e5c6f7a919132ce1e75b7e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/3201522609?pq-origsite=%requestingapplication% |
PMID | 40275167 |
PQID | 3201522609 |
PQPubID | 42582 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_9c77fb00623a46d68b3c0eb83f5ebff0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12020272 proquest_miscellaneous_3194652782 proquest_journals_3201522609 gale_infotracmisc_A837117724 gale_infotracacademiconefile_A837117724 gale_incontextgauss_ISR_A837117724 gale_incontextgauss_IOV_A837117724 pubmed_primary_40275167 crossref_primary_10_1186_s12879_025_10991_7 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-04-24 |
PublicationDateYYYYMMDD | 2025-04-24 |
PublicationDate_xml | – month: 04 year: 2025 text: 2025-04-24 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC infectious diseases |
PublicationTitleAlternate | BMC Infect Dis |
PublicationYear | 2025 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 10991_CR2 DS Mouliou (10991_CR19) 2022; 16 10991_CR18 X Li (10991_CR20) 2024; 470 CC Lai (10991_CR7) 2020; 53 GD Braunstein (10991_CR10) 2021; 63 E Surkova (10991_CR15) 2020; 8 10991_CR9 DS Mouliou (10991_CR17) 2022; 20 JP Skittrall (10991_CR11) 2021; 27 M Marando (10991_CR1) 2020; 7 Y Galipeau (10991_CR5) 2023; 11 R Mogling (10991_CR13) 2020; 26 JF Huggett (10991_CR14) 2020; 66 NNY Tsang (10991_CR3) 2021; 21 P Sen (10991_CR6) 2024; 63 10991_CR21 Z Wang (10991_CR23) 2021; 23 A Tahamtan (10991_CR4) 2020; 20 VP Shah (10991_CR8) 2021; 8 10991_CR12 10991_CR22 DS Mouliou (10991_CR16) 2021; 15 |
References_xml | – volume: 26 start-page: 1944 issue: 8 year: 2020 ident: 10991_CR13 publication-title: Emerg Infect Dis doi: 10.3201/eid2608.201843 – ident: 10991_CR12 doi: 10.1101/2020.04.26.20080911 – ident: 10991_CR18 doi: 10.3390/diseases11010020 – volume: 470 start-page: 134201 year: 2024 ident: 10991_CR20 publication-title: J Hazard Mater doi: 10.1016/j.jhazmat.2024.134201 – volume: 7 start-page: 001680 issue: 7 year: 2020 ident: 10991_CR1 publication-title: Eur J Case Rep Intern Med – volume: 20 start-page: 1163 issue: 9 year: 2022 ident: 10991_CR17 publication-title: Expert Rev anti-infective Therapy doi: 10.1080/14787210.2022.2089653 – volume: 21 start-page: 1233 issue: 9 year: 2021 ident: 10991_CR3 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00146-8 – volume: 63 start-page: e159 issue: 3 year: 2021 ident: 10991_CR10 publication-title: J Occup Environ Med doi: 10.1097/JOM.0000000000002138 – ident: 10991_CR2 doi: 10.3390/v12060582 – volume: 8 start-page: 1167 issue: 12 year: 2020 ident: 10991_CR15 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30453-7 – volume: 63 start-page: e202400413 issue: 20 year: 2024 ident: 10991_CR6 publication-title: Angewandte Chemie (International Ed English) doi: 10.1002/anie.202400413 – volume: 53 start-page: 404 issue: 3 year: 2020 ident: 10991_CR7 publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2020.02.012 – volume: 27 start-page: 469 issue: 3 year: 2021 ident: 10991_CR11 publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2020.10.003 – volume: 8 start-page: ofab453 issue: 9 year: 2021 ident: 10991_CR8 publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofab453 – volume: 66 start-page: 1369 issue: 11 year: 2020 ident: 10991_CR14 publication-title: Clin Chem doi: 10.1093/clinchem/hvaa214 – volume: 15 start-page: 993 issue: 8 year: 2021 ident: 10991_CR16 publication-title: Expert Rev Respir Med doi: 10.1080/17476348.2021.1917389 – ident: 10991_CR9 doi: 10.1183/13993003.00360-2021 – ident: 10991_CR22 doi: 10.2807/1560-7917.ES.2020.25.50.2000568 – ident: 10991_CR21 doi: 10.1128/cmr.00072-23 – volume: 20 start-page: 453 issue: 5 year: 2020 ident: 10991_CR4 publication-title: Expert Rev Mol Diagn doi: 10.1080/14737159.2020.1757437 – volume: 16 start-page: 263 issue: 3 year: 2022 ident: 10991_CR19 publication-title: Expert Rev Respir Med doi: 10.1080/17476348.2022.2049760 – volume: 11 start-page: 1240308 year: 2023 ident: 10991_CR5 publication-title: Front Public Health doi: 10.3389/fpubh.2023.1240308 – volume: 23 start-page: 19 issue: 1 year: 2021 ident: 10991_CR23 publication-title: J Mol Diagn doi: 10.1016/j.jmoldx.2020.10.008 |
SSID | ssj0017829 |
Score | 2.4205372 |
Snippet | RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further... RT-PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further... Background RT-PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives... BackgroundRT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives... Abstract Background RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 593 |
SubjectTerms | Acids Chemical tests and reagents Chi-square test China Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 Nucleic Acid Testing - methods Cycle threshold Data collection Disease control Disease prevention Diseases Epidemics False positive False Positive Reactions Gene amplification Genes Health aspects Humans Israel Laboratories Medical screening Nucleic acids Pandemics Polymerase chain reaction Quality control Reagents Respiratory diseases Retest RT‒PCR SARS-CoV-2 - genetics SARS-CoV-2 - isolation & purification SARS‒CoV‒2 Sensitivity and Specificity Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Synthesis Testing Tubes Viral diseases |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gLovwGCjIIiQOymjiOHR-XiqogFaQurfZm-S_tXhJEsvc-CE_HkzDjZFcbIcSFa2YiJTNjzzce-zMhb73KdePqgvkgBBPcB6aj10xFvAwp5MpZPDt8_kWeXYrPq2q1d9UX7gkb6YFHwx1rr1SDscFLK2SQtSt9Hl1dNlV0TZOqdch522Jq6h9A3tPbIzK1PO5hFlaa4dWt2AkqmJqlocTW_-ecvJeU5hsm9zLQ6QNyf4KOdDF-8iG5E9uH5O751Bx_RK4TVyrFAyMUYB1dLi6W7KS7Ypy2yFq89tT6daAALgc6dHTdImLsY1KOO8pj2jU0AHyEnEZxlTaJf93-nFo5dPWYXJ5-_HZyxqZ7FJiHYmBgEmo4b2XQEg0WfVHFwrlgi1hXIQgUwKivy1LEystGWQ1FXMl9LKKqnIrlE3LQdm18RiiohTLkLtc8ANSzugqAH6rIZY2PRUbeb81qvo90GSaVGbU0oxMMOMEkJxiVkQ9o-Z0mUl2nBxAAZgoA868AyMgb9JtBMosWd8tc203fm09fr8wCqm9sSnPxN6XlxUzp3aTUdOBmb6cTCvDrSJI10zyaacKQ9HPxNobMNCX0pgSohWA31xl5vRPjm7jNrY3dBnQKLWTFIXoz8nQMuZ1xBDaYCwlGq2fBOLPeXNKubxJheMFzXOPiz_-HvV-QexwHUi4YF0fkYPixiS8BmA3uVRqDvwHVXjSl priority: 102 providerName: Directory of Open Access Journals |
Title | Learn from the SARS-CoV-2 nucleic acid test to increase the experience of dealing with the “disease X |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40275167 https://www.proquest.com/docview/3201522609 https://www.proquest.com/docview/3194652782 https://pubmed.ncbi.nlm.nih.gov/PMC12020272 https://doaj.org/article/9c77fb00623a46d68b3c0eb83f5ebff0 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1Nb9Mw1IJNQlwQ33SMyiAkDsha7Dh2fEJttWkgbaCWTRUXK7Gd0ksylva-H8Kv45fwnpuWRQguOdgvUvK-P-z3CHnrdGKqMufMeSmZFM4zE5xhOuAwJJ_ossC7w2fn6vRCfppn8y7h1nbHKrc6MSpq3zjMkR-lYKnQV0jMh6sfDKdGYXW1G6Fxl-xj6zLkaj3fBVwcrJ_ZXpTJ1VELulgbhgNcsR7Eme4Zo9iz_2_NfMs09Y9N3rJDJw_Jg86BpKMNxR-RO6F-TO6ddSXyJ2QRO6ZSvDZCwbmjs9F0xibNJRO0xt7FS0cLt_QUXMwVXTV0WaPf2IYIHHaNj2lTUQ9OJFg2irnauP3r5mdX0KHzp-Ti5Pjr5JR10xSYg5BgxRREcq5Q3qiyqpLgeBZ4WfqChzzzXuIGyH6epjJkTlW6MBDKpcIFHnRW6pA-I3t1U4cXhAKYT31SJkZ4cPgKk3nwIrIgVI7LckDeb9FqrzZNM2wMNnJlN0SwQAQbiWD1gIwR8ztIbHgdF5rrhe3kxxqndYUqQqQFfKvKy9QloczTKgv4PwPyBulmsaVFjWdmFsW6be3Hz5d2BDE4lqaF_BfQbNoDetcBVQ2Q2RXdPQX4dWyV1YM87EGCYLr-9paHbKcYWvuHjQfk9W4b38TDbnVo1gDDjVSZAO4dkOcbltshR2KZmStAWt5jxh72-jv18ntsG85FgpkucfD_73pJ7gsUkUQyIQ_J3up6HV6B47Uqh1G64JlP-JDsj4_Pv0yHMYkBz-n422-rxy-k |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1Nb9Mw1BpDAi6IbzoGGATigKwljmPHB4RKYWrZOqR1m3ozie10vSRjaYW48UP4DfwofgnvpUlZhOC2a95rlbxv-30R8sKqQOdZEjLrhGCCW8e0t5opj8uQXKCyFHuHxwdyeCw-TuPpBvnZ9sJgWWVrE2tD7UqLd-Q7EXgqjBUC_fbsC8OtUZhdbVdorMRiz3_7Cke26s3oPfD3Jee7H44GQ9ZsFWAWQuMFk3Cisal0WmZ5Hngbxj7MMpeGPomdEwgAHUiiSPjYylylGo40Ebc-9CrOlI_gf6-QqyIC1cTO9MG6pCQEb6vbxpxE7lRg-5VmuDAW808hUx3nV-8I-NsTXHCF3TLNC35v9xa52QSstL-SsNtkwxd3yLVxk5K_S2b1hFaKbSoUgkk66R9O2KA8YZwWOCt5bmlq545CSLugi5LOC4xTK18j-_WgZVrm1EHQCp6U4t1wDf71_UeTQKLTe-T4Uuh8n2wWZeEfEgpoLnJBFmjuIMBMdewgaok9lwk-Fj3yuiWrOVsN6TD14SaRZsUEA0wwNROM6pF3SPk1Jg7Yrh-U5zPT6KvRVqkcTRKPUnhXmWSRDXyWRHns8Xt65DnyzeAIjQJrdGbpsqrM6NOJ6cOZH1PhXPwLaXLYQXrVIOUlsNmmTV8EfDqO5upgbncwwRDYLriVIdMYosr8UZseebYG4y-xuK7w5RJwQi1kzEF6e-TBSuTWxBGY1g4lEC3pCGOHel1IMT-tx5SHPMCbNb71__d6Sq4Pj8b7Zn90sPeI3OCoLoFgXGyTzcX50j-GoG-RPak1jZLPl63avwGmCWiM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Learn+from+the+SARS-CoV-2+nucleic+acid+test+to+increase+the+experience+of+dealing+with+the+%E2%80%9Cdisease+X&rft.jtitle=BMC+infectious+diseases&rft.au=Yang%2C+Xin&rft.au=Li%2C+Jinming&rft.date=2025-04-24&rft.pub=BioMed+Central&rft.eissn=1471-2334&rft.volume=25&rft.spage=1&rft_id=info:doi/10.1186%2Fs12879-025-10991-7 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |